ライフサイエンスコーパス: bipolar depression

1 d six trials representing 1383 patients with bipolar depression.

2 d, placebo-controlled study of patients with bipolar depression.

3 macological treatment in treatment-resistant bipolar depression.

4 ceptor in vivo, and lower receptor number in bipolar depression.

5 efficacy of midday bright light therapy for bipolar depression.

6 effects in patients with treatment-resistant bipolar depression.

7 relates of manic symptoms during episodes of bipolar depression.

8 djunctive bright light therapy at midday for bipolar depression.

9 ving adjunctive antidepressant treatment for bipolar depression.

10 tability in patients receiving treatment for bipolar depression.

11 before starting antidepressant treatment in bipolar depression.

12 ef treatment in enhancing stabilization from bipolar depression.

13 and/or release in mania and DAT blockade in bipolar depression.

14 n transporters are first-line treatments for bipolar depression.

15 lihood of remaining well after an episode of bipolar depression.

16 risperidone in improving treatment-resistant bipolar depression.

17 ns for the management of treatment-resistant bipolar depression.

18 ls of adjunctive antidepressant treatment of bipolar depression.

19 r or an antipsychotic in patients with acute bipolar depression.

20 effective antidepressant among patients with bipolar depression.

21 ficacy of pramipexole in treatment-resistant bipolar depression.

22 enefit ratio for antidepressant treatment of bipolar depression.

23 are effective in the short-term treatment of bipolar depression.

24 tidepressants in the short-term treatment of bipolar depression.

25 lly offers improved outcomes for people with bipolar depression.

26 udies have examined treatment strategies for bipolar depression.

27 yroid function will facilitate recovery from bipolar depression.

28 Cycle acceleration occurred only in bipolar depression (25.6%), with new rapid cycling in 32

29 , 89 adults were included, including 27 with bipolar depression, 25 with unipolar depression, and 37

30 In bipolar depression accompanied by manic symptoms, antide

31 use at admission included epilepsy/seizure, bipolar depression, age group, and cognitive performance

32 iation included epilepsy/seizure indication, bipolar depression, age group, peripheral vascular disea

33 dimensions and factor structure of mania and bipolar depression and (2) longitudinal studies reportin

34 f antidepressant trials for 41 patients with bipolar depression and 37 with unipolar depression, simi

35 Unipolar/bipolar depression and a history of attempted suicide we

36 to determine the association of unipolar and bipolar depression and a history of attempted suicide wi

37 of competing options for treatment-resistant bipolar depression and assesses the effectiveness and sa

38 Bipolar depression and major depressive disorder exhibit

39 hologically complex clinical state than pure bipolar depression and merit recognition as a distinct n

40 been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controll

41 drome, Angelman syndrome, Turner's syndrome, bipolar depression and schizophrenia.

42 ganglia are consistent with MRS findings in bipolar depression and suggest that inflammatory cytokin

43 ine coexisting with otherwise full syndromal bipolar depression are associated with antidepressant tr

44 rticipants with bipolar mania (BM) (n = 30), bipolar depression (BD) (n = 30), bipolar euthymia (BE)

45 y differentiate unipolar depression (UD) and bipolar depression (BD) remain unidentified.

46 nts with major depressive disorder (MDD) and bipolar depression (BD).

47 cated adults were recruited: 30 with current bipolar depression (BPD), 30 with current bipolar hypoma

48 Manic switching occurred only in bipolar depression but happened less in patients taking

49 ans and patients to consider lamotrigine for bipolar depression, but also to be aware that concurrent

50 effective treatment for treatment-resistant bipolar depression, but no randomized controlled trials

51 re associated with reduced symptoms of acute bipolar depression, but the magnitude of benefit is smal

52 ntidepressants is widely used to treat acute bipolar depression, but their efficacy and safety remain

53 AChR availability (20%-38%) in subjects with bipolar depression compared with euthymic and control su

54 Currently, no pharmacological treatments for bipolar depression exist that exert rapid (within hours)

55 Existing therapies for bipolar depression have a considerable lag of onset of a

56 e episodes associated with bipolar disorder (bipolar depression) have not been well studied.

57 ctivity is associated with both unipolar and bipolar depression; however, the function of POase in th

58 In bipolar depression imaging studies show increased dopami

59 ine with that of placebo in the treatment of bipolar depression in adult outpatients stabilized on a

60 e from the STEP-BD randomized trial for pure bipolar depression, in which adjunctive antidepressants

61 es in cholinergic signaling in subjects with bipolar depression may improve our understanding of its

62 em resting connectivity between unipolar and bipolar depression may reflect differential risk of mani

63 were genotyped in additional schizophrenia, bipolar, depression (n > 1600), and control (n > 950) co

64 cing a major depressive episode (unipolar or bipolar depression) of at least 2 years' duration or had

65 Lower serotonin transporter BP(1) in bipolar depression overlaps with that observed in major

66 omized controlled trial of psychotherapy for bipolar depression, participants received up to 30 sessi

67 While guidelines for treating patients with bipolar depression recommend discontinuing antidepressan

68 rations in serotonergic neurotransmission in bipolar depression remains scant.

69 In patients with treatment-resistant bipolar depression, robust and rapid antidepressant effe

70 vothyroxine (L-T4) to standard treatment for bipolar depression shows promise, but the mechanisms und

71 Eighty-five patients with bipolar depression that was inadequately responsive to a

72 ed study, we randomly assigned subjects with bipolar depression to receive up to 26 weeks of treatmen

73 studies involving subjects with unipolar or bipolar depression treated with parenteral doses of scop

74 Patients Eighteen subjects with DSM-IV bipolar depression (treatment-resistant).

75 Bipolar depression was associated with family history of

76 Adjunctive treatment with antidepressants in bipolar depression was associated with substantial risks

77 Forty-eight patients with unipolar or bipolar depression were treated with a course of bifront

78 ficacy and safety of adjunctive modafinil in bipolar depression, which is often characterized by exce

79 ated our previous finding that patients with bipolar depression who received a single ketamine infusi

80 for SAD and DSM-III-R criteria for major or bipolar depression with seasonal pattern had their level

81 ized, double-blind trial in 60 patients with bipolar depression, with SWM as the primary outcome meas

82 e antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania.